GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).
Ciara ConduitBlossom MakWenjia QuJuliana Di LulioRonan BurderMatthias BresselThomas CusickHaryana M DhillonRichard De Abreu LourençoCraig UnderhillJavier TorresMegan CrumbakerFlorian HoneyballAnthony LintonRay AllenIan D DavisSusan J ClarkLisa G HorvathKate L MahonPublished in: Therapeutic advances in medical oncology (2022)
as a novel biomarker to guide treatment de-escalation in metastatic CRPC.
Keyphrases
- open label
- clinical trial
- squamous cell carcinoma
- small cell lung cancer
- phase ii
- double blind
- study protocol
- healthcare
- locally advanced
- phase iii
- randomized controlled trial
- placebo controlled
- palliative care
- quality improvement
- high intensity
- pain management
- rectal cancer
- affordable care act
- chronic pain
- smoking cessation